The US is the largest national market for somatostatin-based therapies, driven by high diagnosis rates of neuroendocrine tumors (NETs), acromegaly, and carcinoid syndrome. Octreotide, lanreotide, and pasireotide are well established in clinical practice, supported by strong reimbursement, specialist access, and a large base of endocrinology and oncology centers. Somatostatin-receptor-targeted...